MMP-14 Binding Proteins for Osteolytic Lesion Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteolytic disorders, particularly osteotropic cancer and osteoporosis, are inadequate as they do not effectively prevent or treat bone metastases, leading to significant side effects and limited life-prolonging benefits.
Innovation Solution
Administration of MMP-14 or MMP-9 binding proteins, either alone or in combination with other cancer therapeutics, to inhibit osteoclast activity and prevent the formation or progression of osteolytic lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonates are used to inhibit bone resorption, then bone resorption is inhibited and osteoclast activity is suppressed, but significant side effects occur and life-prolonging benefits are limited
Solution Approach 1:
The patent introduces MMP-14 binding proteins as intermediary molecules that specifically target and inhibit MMP-14 enzyme activity in the bone microenvironment. This mediator approach allows selective inhibition of osteoclast-mediated bone resorption without the systemic toxic effects of bisphosphonates, as the binding protein acts locally at the site of osteolytic lesions rather than affecting all osteoclasts throughout the body
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific osteoclast inhibition (bisphosphonates) to specific MMP-14 enzyme inhibition (binding proteins). This parameter change from broad suppression to targeted inhibition maintains therapeutic effectiveness while reducing harmful side effects by selectively targeting the pathological process without affecting normal bone remodeling
2Ease of operation
If existing treatments like chemotherapy and radiotherapy are used for bone metastases, then quality of life is improved, but life-prolonging benefits are not achieved and significant side effects occur
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (MMP-14-mediated bone matrix degradation) responsible for osteolytic lesions, separating this targeted intervention from the systemic effects of chemotherapy and radiotherapy. By taking out the specific enzymatic pathway for inhibition, the treatment addresses the root cause of bone destruction without the broad toxic effects of conventional cancer therapies
Solution Approach 2:
The patent converts the harmful effect of MMP-14 (which promotes tumor growth and bone destruction in the bone microenvironment) into a therapeutic target. By specifically inhibiting MMP-14, the treatment transforms the pathological process into a beneficial therapeutic mechanism that protects bone integrity and may inhibit tumor progression without the harmful side effects of conventional treatments
3Reliability
If osteoclast activity is suppressed to prevent bone resorption, then osteolytic lesions are inhibited, but normal bone remodeling processes are also affected
Solution Approach 1:
The patent applies local quality by targeting MMP-14 specifically in the bone microenvironment where osteolytic lesions occur. The MMP-14 binding protein acts locally at the site of pathological bone resorption rather than systemically suppressing all osteoclast activity. This localized inhibition preserves normal bone remodeling in unaffected areas while preventing osteolytic lesion formation at the target site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of MMP-14 or MMP-9 binding proteins effectively decreases the occurrence and severity of osteolytic lesions, offering a more targeted and potentially less toxic approach to managing osteolytic disorders compared to existing treatments.
Implementation Method 1
Administration of MMP-14 or MMP-9 binding proteins, either alone or in combination with other cancer therapeutics, to inhibit osteoclast activity
Data Source
AI summary
Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.